Population-based evidence on second cancer risk following autologous haematopoietic SCT (HCT) is lacking. We quantified second cancer risk for a national, population-based cohort of adult Australians receiving autologous HCT for cancer and notified to the Australasian Bone Marrow Transplant Recipient Registry 1992Registry -2007. Cancer diagnoses and deaths were ascertained by linkage with the Australian Cancer Database and National Death Index. Standardized incidence ratios (SIRs) were calculated and Cox regression models were used to estimate within-cohort risk factors treating death as a competing risk. During a median 2.5 years follow-up, second cancer risk was modestly increased compared with the general population (SIR 1.4, 95% confidence interval 1.2-1.6); significantly elevated risk was also observed for AML/myelodysplastic syndrome (SIR ¼ 20.6), melanoma (SIR ¼ 2.6) and non-Hodgkin lymphoma (SIR ¼ 3.3). Recipients at elevated risk of any second cancer included males, and those transplanted at a younger age, in an earlier HCT era, or for lymphoma or testicular cancer. Male sex, older age (445 years) and history of relapse after HCT predicted melanoma risk. Transplantation for Hodgkin lymphoma and older age were associated with lung cancer risk. Second malignancies are an important late effect and these results inform and emphasize the need for cancer surveillance in autologous HCT survivors.
INTRODUCTION
Autologous haematopoietic SCT (HCT) is increasingly being used in Australia and elsewhere as a therapy for several haematopoietic and solid organ malignancies. 1, 2 Life expectancy following HCT has also improved, 3 increasing the number of HCT survivors globally. Characterizing late effects and identifying those at risk will maximize the long-term health of HCT recipients.
Second cancers are a recognized late effect of chemo-radiation therapy in general, and in the HCT setting specifically. [4] [5] [6] [7] [8] [9] [10] [11] The cumulative incidence of second cancer after autologous HCT may be as high as 29% after 15 years, 11 with the greatest excess risk observed for AML and myelodysplastic syndromes (MDSs). 10, [12] [13] [14] [15] Most prior studies have examined second cancer risk in recipients of allogeneic and autologous HCT, with the largest based on international transplant registry cohorts. 9 Furthermore, most studies ascertained second cancers from hospital records or by self-report, potentially under-estimating risk. There are no population-based estimates of the risk of secondary cancer in adult recipients of autologous HCT. We examined the incidence and risk factors for second cancer in a national, population-based cohort of 7765 adult Australian autologous HCT recipients, 1992-2007.
MATERIALS AND METHODS

Study population
The Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) records up to 99.5% of HCTs performed in Australia since 1992. 16 Our cohort included adult (X15 years) recipients of a single or staged/tandem autologous HCT for a haematological or solid cancer between 1992 and 2007, the latest date for which cancer registrations were available (n ¼ 8442). Recipients whose malignant indication for transplantation was not identified in linkage with the Australian Cancer Database were excluded (n ¼ 677, 8.0%).
Data collection
Demographic and clinical data collected by ABMTRR were utilized for this study. Deaths and incident cancers were ascertained by record linkage with population-based data sets; the National Death Index and the Australian Cancer Database , a register of incident primary invasive neoplasms, other than basal and squamous cell carcinoma of the skin. The Australian cancer registries apply international rules when registering multiple primary cancers. Solid cancers were classified according to the International Classification of Diseases (ICD), 10th revision, while haematopoietic neoplasms and Kaposi sarcomas were classified according to the ICD for Oncology, third edition. Registrant's name code (first two letters of given name and first four letters of surname), sex, date of birth, date of death and state of residence were used for probabilistic record linkage. Cancer incidence rates for the Australian general population were obtained from the Australian Cancer Database. Ethical approval was obtained and the requirement for informed consent was waived because the researchers received only de-identified data.
cancers. Potential progressed primary malignancies were assessed and excluded. The probability of second cancer was estimated by computing the cumulative incidence, treating death from other causes as a competing risk. Probabilities were calculated from the date of HCT to the date of second cancer diagnosis, death or censoring (31 December 2007) .
Person-years follow-up accrued from transplantation (or day 31) until the date of second cancer diagnosis, death, or 31 December 2007, whichever occurred first. The standardized incidence ratio (SIR), the ratio of the observed and the expected numbers of cancers, was generated for all cancers and for specific cancers. The expected numbers of incident cancers were calculated by multiplying the number of person-years at risk by the corresponding 5-year age-specific, sex-specific, state-specific and calendaryear-specific cancer incidence rates for the Australian population. All second and higher-order cancers were counted; recipients did not contribute person-years at risk for their pre-HCT cancer type. Select analyses were also performed for the four most common indications for transplantation.
Risk factor analysis for the most common second cancers used multivariate Cox regression modelling with adjustment for competing risk of death, and proportional hazards assumption testing for each covariate. Relapse of the transplant indication and any subsequent transplantation were treated as time-dependent covariates.
Analyses were performed using STATA, Version 12 (StataCorp, College Station, TX, USA).
RESULTS
The 7765 HCT recipients accumulated 28 945 person-years follow-up, a median of 2.5 person-years per recipient (interquartile range, 0.8-5.4). In all, 48% (n ¼ 3708) of recipients died during follow-up and 30% (n ¼ 2320) within 2 years of transplantation. The median age at HCT was 52 years (range, 15-81) with 470% transplanted for non-Hodgkin lymphoma (NHL) or multiple myeloma (MM; Table 1 ).
We observed 298 second primary cancers in 287 patients, a median of 3.0 years after HCT (range, 0.1-14.6). The majority were solid tumours (n ¼ 236, 79%) and melanoma was the most common (n ¼ 55). AML/MDS (n ¼ 50) accounted for 81% of the incident haematological malignancies.
Cumulative incidence
The 10-year and overall cumulative incidence of second cancers was 5.28% (95% confidence interval (CI) 4.65-5.97) and 7.31% (95% CI 6.10-8.66) for all cancers, 4.22% (95% CI 3.64-4.86) and 5.70% (95% CI 4.80-6.71) for solid cancers, and 1.17% (95% CI 0.89-1.51) and 1.78% (95% CI 1.02-2.90) for haematological malignancies, respectively ( Figure 1 ).
Risk relative to the general population Overall risk of second cancer relative to the general population was modestly elevated (SIR 1.38, 95% CI 1.23-1.55; Table 2 ). Risk was highest for those aged 15-29 years and there was no excess risk for patients aged at least 60 years. Males, but not females, exhibited an excess cancer risk. The excess cancer risk declined with more recent calendar periods of transplantation, with no excess for the most recent transplant era examined (2004) (2005) (2006) (2007) . Second cancer risk increased with increasing time since transplantation and remained elevated 410 years after HCT (Table 3) .
Excess risk was observed for AML/MDS, melanoma and NHL, whereas rates for breast cancer were lower than those in the general population (Figure 2 ). The risk of melanoma was highest for the trunk (SIR 3.20, 95% CI 2.16-4.74), then the head and neck (SIR 2.96, 95% CI 1.59-5.50) and limbs (SIR 1.88, 95% CI 1.18-2.98). An excess risk of melanoma (all sites, trunk and limbs) was observed only within 4 years of HCT. The risk of AML/MDS was elevated across all time intervals from HCT and was greatest within 4 years of HCT (Table 3) . NHL risk was significantly elevated within 1 year of HCT, but not thereafter. Three cancers were increased in risk only during certain time intervals from HCT; Other solid cancers include: abdominal germ cell tumour (3), astrocytoma (5), glioblastoma (1), central nervous system tumour (5), rectum carcinoma (1), choriocarinoma (6), desmoid small cell tumour (2), ependymoma (2), esthesioneuroblastoma (1), germ cell tumour-unknown primary (7), germ cell tumourextragonadal (6), hepatoblastoma (1), intracranial germ cell tumour (4), lung carcinoma (12), mediastinum germ cell tumour (13), medulloblastoma (16) , melanoma (1), merkel cell carcinoma (1), mixed germ cell tumour (1), mixed germ cell tumour-testis (15), myoepithelial sarcoma (1), nasopharyngeal carcinoma (1), neuroblastoma (5), neuroendocrine tumour (3), osteosarcoma (15) , ovarian carcinoma (29) , ovarian germ cell tumour (6), primitive neuroectodermal tumour (7), paragaglioma (1), pinealoblastoma (3), pulmonary germ cell tumour (1), rhabdomyosarcoma (27) , seminoma (15) , small cell tumour (4), soft tissue sarcoma (18) , synovial sarcoma (2), teratoma (2), testicular germ cell tumour (13), thymic cancer (2), undifferentiated solid malignancy (1) and Wilm's tumour (3). c Other myeloid malignancies include: acute biphenotypic leukaemia (4), myelodysplasia (14) and chronic myelofibrosis (4).
rectal/anal cancers (1-4 years after HCT), oral and pancreatic cancers (5-9 years), and lung cancer (10 þ years).
Stratification of SIRs by HCT indication showed elevated overall cancer risk in patients transplanted for Hodgkin lymphoma (HL), NHL and testicular cancer ( Table 2) . Lung cancer risk increased in patients transplanted for NHL or HL (Table 4) . AML/MDS risk was elevated at least 10-fold in patients transplanted for HL, NHL, MM or breast cancer (Table 4) . Excess melanoma risk was observed in patients transplanted for NHL, MM or HL (Table 4) .
A sensitivity analysis to evaluate the effect of excluding patients whose transplant indication recorded by the ABMTRR was not identified by linkage with the Australian Cancer Database showed a negligible effect on the SIRs (data not shown).
Within-cohort risk, adjusted for competing risk of death None of the demographic or clinical variables available for analysis was significantly associated with risk of AML/MDS after autograft. Females were at half the risk of melanoma compared with males, while patients aged 45 years or more at HCT were at double the risk compared with those o45 years (Table 5) . Patients with a history of relapse after HCT were also at reduced risk of melanoma. Lung cancer risk was elevated in those aged over 45 years, and in recipients transplanted for HL. We observed no association with risk of AML/MDS, melanoma or lung cancer in relation to stem cell source, HCT era, subsequent HCT, persistent disease after HCT or type of HCT (single or staged).
When these analyses were repeated for the two most common indications (NHL, MM), risk of AML/MDS after autograft for MM was increased in those with a history of relapse (subdistribution hazard ratio 3.74, 95% CI 1.19-11.7) and reduced in those transplanted since 2000 (subdistribution hazard ratio 0.27, 95% CI 0.08-0.90). Risk of melanoma was reduced for females transplanted for NHL (subdistribution hazard ratio 0.24, 95% CI 0.07-0.82).
DISCUSSION
In this national, population-based cohort study, autologous HCT in adults treated for solid or haematopoietic cancer was associated with a modest increased risk of second cancer. Overall, rates of melanoma, AML/MDS and NHL were elevated relative to the matched general population. Lung cancer risk was increased, but only in those surviving at least 10 years after HCT. Other key findings include an elevated risk in men, young adults, and in patients transplanted for NHL, HL and testicular cancer compared with the general population. Although overall risk increased with increasing time from transplantation, risk for the most common second cancers, AML/MDS and melanoma, was highest during the first 4 post transplant years. In within-cohort analyses, HCT characteristics did not predict second cancer risk, but HCT population subgroups at greatest risk for second cancer were identified.
There are no prior population-based studies of second cancer risk in adult autologous HCT, and no reliable risk estimates for sitespecific solid cancers. Previous studies from single centres in Canada may reflect the population-level risk given the regional centralization of Canadian HCT services. One such study reported an elevated risk of AML and any solid cancer for 372 NHL patients, 14 while another reported an increased risk of AML/MDS, lymphoproliferative disorders and solid cancer among 800 recipients treated for a variety of indications. 12 A multicentre hospital-based Italian study examined second cancer risk after high-dose chemotherapy and HCT, with or without rituximab (n ¼ 1024), and also showed an elevated risk of AML/MDS and any solid cancer. 15 Prior large-scale non-population-based studies have examined both adult and child HCT recipients, and more importantly allogeneic and autologous HCT recipients together, making inferences about second cancer risk in adult autologous HCT recipients difficult. 4, [6] [7] [8] 13, 17 Other reports of second cancer rates after autologous HCT have not statistically compared the observed cancer rates with those of the general population. 10, 11, 18, 19 Compared with the general population, we found an elevated second cancer risk in males, young adults and the earlier transplant eras. The high numbers of males transplanted for HL, NHL and testicular cancer may have influenced this finding to some extent, as these indications also had an increased second cancer risk. An excess risk in men is consistent with nonpopulation-based studies in adult NHL patients undergoing autograft 15 and allogeneic HCT recipients. 9 Paediatric autograft recipients also show a significant excess cancer risk compared with the general population, 20 and studies of allogeneic HCT recipients have reported an elevated second cancer risk in younger adults, including young patients receiving conditioning TBI. 9 The increased cancer risk for the earlier transplant eras may reflect changing autologous HCT regimens over time, with a move away from TBI in more recent years, in addition to a longer followup time for the earlier sub-cohorts.
Survivors of testicular cancer, NHL and HL have an elevated second cancer risk irrespective of the therapeutic approach. 
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Without data on previous therapies, it is not possible to determine the relative contribution of autologous HCT to cancer risk above that due to chemo-radiotherapy. A trial examining indolent lymphoma patients randomly assigned to autologous HCT or IFN maintenance found an increased risk of secondary haematological malignancy in the autologous HCT arm, 25 suggesting an association with HCT, possibly TBI conditioning. We found no overall increased risk of second cancer in patients transplanted for MM, where autologous HCT is used relatively early in the disease course. In contrast, we observed an elevated risk of second cancer in NHL, HL and testicular cancer patients, where autologous HCT is generally reserved for relapsed or refractory disease. These findings suggest the cumulative dose and type of prior therapy may be more important than autologous HCT per se for second cancer risk.
Melanoma risk is increased in NHL patients 11, 24 and after allogeneic HCT, 4, 6, 8, 9 allogeneic/autologous HCT 4, 6, 8 and solid organ transplantation. 26 In our study, melanoma risk was elevated in patients transplanted for NHL or MM, but only during the first 4 post transplant years, similar to the pattern over time after kidney transplantation. 27 The risk factors for melanoma were older age and male sex, characteristics that predict melanoma risk in the general population, 28 and correlates of higher cumulative sun exposure. Immune dysregulation during prior chemotherapy and HCT may underlie the increased risk of this immunogenic neoplasm, a hypothesis that is supported by excess acquired melanocytic naevi in immune suppressed patients including chemotherapy recipients. 29, 30 Shared risk factors between melanoma and the primary cancers may also have a role, but do not readily explain the trend over time since HCT.
An elevated risk of AML/MDS has been reported by almost all studies of second cancer after autologous HCT, with risk associated with older age and cumulative exposure to alkylating agent-based chemotherapy. 31 We did not observe an association with older age, possibly because our study population excluded paediatric recipients. Risk of AML/MDS was increased for a number of indications including MM, the most common current indication for autologous HCT. Several large population-based studies have reported an increased second cancer risk in MM regardless of the type of therapy, especially AML/MDS. 32, 33 A recent Swedish study showed a modest increased risk of haematological and solid malignancies after MM, and intriguingly also after monoclonal gammopathy of undetermined significance, suggesting nontreatment factors may account for some of the excess risk. 34 Of note, second cancer risk in MM patients may increase in future given the increased risk in those treated with lenalidomide maintenance therapy after HCT. 35, 36 Lung cancer risk increased sixfold in those surviving at least 10 years after transplantation and the risk factors were transplantation for HL and older age at HCT. An increased lung cancer risk in patients treated for HL regardless of the type of therapy has been well described, with risk independently associated with chemotherapy, radiotherapy, cigarette smoking and older age. 37 Consistent with population-based data on cancer risk after haematological malignancy 32 and after solid organ transplantation, 26 we observed no excess breast or prostate cancer risk. Although one study reported more of these cancers than expected in autologous HCT (n ¼ 605), 11 the cohort was confined to patients receiving TBI conditioning, a therapy that increases breast cancer risk in the allogeneic HCT setting. 38 This is the first study to identify a significant reduction in breast cancer risk after autologous HCT. There is no known biological explanation for this finding, and the similar rates of breast cancer screening in HCT recipients and matched controls 39 suggests it is not an artefact of surveillance. An increased risk of oropharyngeal cancer has been consistently reported after allogeneic HCT 9 and was also observed in our study, but only in those surviving 5-9 years after HCT and despite the absence of oral GVHD in autograft.
Our findings support the application of consensus guidelines for the screening and follow-up of long-term HCT survivors. 40 Established general population screening programs are likely to be at least as effective in the HCT population. The guidelines recommend regular patient education about high-risk behaviours such as sun exposure and cigarette smoking, vigilance for new signs and symptoms, and annual clinical assessment. We also recommend formal skin check by an expert physician or dermatologist at least annually, with monthly skin selfexamination. Our results provide no strong evidence for lung cancer surveillance other than having a low clinical threshold for further investigations if compatible symptoms develop, perhaps targeting high-risk subgroups such as those transplanted for HL or heavy smokers. Figure 2 . SIRs of specific second cancers after autologous HCT. jet., junction.
The strengths of this study are the inclusion of only autograft recipients, and the population-based design, rendering the findings generalizable to the Australian autograft population. As Australian autograft practices are similar to those in other countries of similar socioeconomic status, our findings are also likely to be broadly generalizable. Moreover, although rates of melanoma are higher in Australia compared with most other countries, the SIR calculations have taken this into account. With over 7000 recipients and almost 300 second primary malignancies, we had adequate statistical power to examine the risk factors for specific cancers. Study limitations include the use of a name code for record linkage, leading to missing and incorrect links in a small proportion of cases, and also that the risk of incident cutaneous squamous cell carcinoma and basal cell carcinoma could not be estimated. In addition, we could not account for race, HCT conditioning, pre-HCT therapies or risk factors for cancer such as sun exposure history and smoking history in our within-cohort analyses. Overestimation of cancer incidence due to increased medical surveillance in HCT recipients compared with the general population cannot be excluded, 39 but the absence of an excess risk of breast or prostate cancer argues against a strong effect. Finally, the median follow-up time is relatively low for a cancer incidence study but this reflects the relatively high mortality rate for the cohort.
In summary, we identified a modest overall increased risk of second cancers in autologous HCT recipients. The excess risk was greatest in patients transplanted for NHL, HL and testicular cancer, with melanoma and AML/MDS being the most common second cancers. The findings are relevant to new autograft recipients as well as those surviving HCTs performed over the last two decades. Screening and late-effects programs after autograft should incorporate these findings to improve the long term outcomes for these patients. Other cancer primary diagnosis category includes ALL; AML; testicular cancer; Ewing's sarcoma; myeloid neoplasms included in 'other myeloid malignancy' primary diagnosis category in Table 1 ; and solid cancers included in 'other solid cancer' primary diagnosis category in Table 1 .
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